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Abstract: The major determinant of the decline in lung function, quality of life, and the increased 
mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, 
that is, those requiring patients’ hospitalization, constituting a substantial social and health care 
burden in terms of morbidity and medical resource utilization. Different long-term therapeutic 
strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact 
of these events, the majority of which were extrapolated from trials initially focused on the effect 
of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists 
in combination or not with inhaled corticosteroids. The option to employ all three classes of mol-
ecules combined, despite the limited amount of evidence in our possession, represents a choice 
currently proposed by international guidelines; however, current recommendations are often 
based mainly on observational studies or on the results of secondary outcomes in randomized 
controlled trials. The present narrative review evaluates the available trials that investigated the 
efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a 
particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose 
combination, which is the first treatment that comprises all the three drug classes, specifically 
tested for the prevention of moderate and severe COPD exacerbations.
Keywords: hospitalization, COPD, triple therapy, inhaled corticosteroids, formoterol, 
glycopyrronium
Introduction
Acute exacerbations of COPD (AECOPDs) represent an acute event characterized by 
a rapid worsening of a patient’s clinical state that requires a medical intervention of 
different intensity depending on the severity of the event and on the patient’s basic 
condition.1 The real incidence of these events is difficult to measure, especially for 
the less severe cases that are certainly underestimated and underreported, being often 
documented in ,50% of cases.2
The cost of AECOPDs represents the 50% of the direct economic burden of COPD;3 
however, the cost increases up to 70% for exacerbations that require hospitalization3 – 
that is, severe exacerbations – and for the management of early recurrence, with a 
leading increasing cost of 18%.4
The prognosis of patients with COPD is influenced by the severity and recur-
rence of the exacerbation, with 1-year mortality rates ranging from 11% for patients 
who need hospitalization5 to 50% for patients subjected to mechanical ventilation.6 
On the contrary, mortality increases up to 37% when hospitalization is needed in 
case of recurrent AECOPD.7 A prospective management strategy aimed at reducing 
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the severity and the number of AECOPDs, with a particular 
focus on moderate and severe exacerbations, is needed in 
order to improve the patients’ prognosis in terms of quality 
of life (QoL), disease progression and mortality, as well as 
the reduction in health care costs and the overall economic 
and social disease burden.
Nowadays, a consistent number of treatments have dem-
onstrated this ability and are therefore suggested for the 
reduction of the rate and severity of acute exacerbations in 
patients with COPD. Nonetheless, to date, outcome-driven 
evidence coming from randomized clinical trials are limited, 
often leaving to the individual the clinical decision-making 
on the choice for the most appropriate treatment strategy to 
be used for patients with COPD at risk of exacerbation. 
This narrative review explores the current evidence about 
the available pharmacological treatments for the preven-
tion of AECOPDs, with a special focus on triple therapy 
and in particular on the combination of beclomethasone 
dipropionate (BDP)/formoterol (FORM)/glycopyrronium 
bromide (GLY).
Role of inhaled corticosteroids 
(ICS) containing therapies in the 
prevention of exacerbations
The indications for ICS containing therapies for patients with 
COPD have greatly changed during the last 15 years. Earlier, 
the widespread use of long-acting β2-agonists (LABA) in 
combination with ICS was initially based upon the evidence 
of their efficacy in reducing AECOPD and hospitalizations.8,9 
Subsequently, the UPLIFT trial demonstrated that also 
tiotropium (TIO), the first approved long-acting muscarinic 
antagonist (LAMA), was able to reduce the risk of AECOPD, 
making it a valid and safe alternative to the therapy with 
ICS/LABA.10,11 
Previously, the growing evidence about efficacy and 
safety of LABA/LAMA fixed combinations and the increased 
risk of pneumonia linked with ICS-containing regimens 
further restricted the indication for ICS therapy, which was 
confirmed in patients at high risk of AECOPD that remained 
symptomatic or had severe airflow obstruction despite an 
initial trial with LABA/LAMA combinations.
The last release of the GOLD recommendations1 suggests 
that COPD patients at high risk of exacerbations – that is, 
patients with two or more AECOPD in the last 12 months – may 
benefit from the triple therapy, although the initial approach 
should always be based upon LABA/LAMA. Recently, 
expert opinion-based algorithms suggested that patients 
who would benefit more from ICS-containing therapies were 
patients with asthma–COPD overlap or with increased blood 
eosinophil counts.12,13
The indication toward the efficacy of ICS in preventing 
AECOPD, and especially severe exacerbations leading to 
hospitalization, has not always been inferred from random-
ized controlled trials (RCTs) that had as a primary outcome 
a reduction in the exacerbations rate. Moreover, throughout 
the years, the heterogeneity of patients enrolled and a non-
univocal definition of exacerbation determined contrasting 
results or data difficult to be interpreted in light of a real-life 
setting (Table 1).
In 2007, the results of the Towards a Revolution in 
COPD Health (TORCH) study were published.9 This was 
the first study that tested the twice daily (BID) fluticasone 
propionate/salmeterol (FP/SALM) 500/50 µg combination 
treatment in a consistent number of COPD patients. The 
primary outcome of the trial was mortality rate, which was 
not met, but at the end of the 3-year follow-up, patients 
in the combination treatment group had the lowest annual 
rate ratio of moderate and severe exacerbations (-25% vs 
placebo). The annual rate ratio for the FP/SALM arm was 
also significantly lower compared with SALM or FP alone 
(risk ratio [RR] 0.88 and 0.91, respectively). The advantage 
of the combination treatment over SALM alone, however, 
seemed to be no longer present when severe exacerbations 
were separately considered. Nonetheless, the trial proved 
that ICS-containing regimens, but not ICS alone, were effica-
cious in reducing hospitalization due to severe AECOPDs, 
improving QoL and lung function in patients with moderate 
to severe COPD. 
In the same year, the Canadian Optimal Therapy of COPD 
Trial (OPTIMAL study) tested and compared the efficacy 
of FP/SALM 50/500 µg BID with TIO 18 µg and the free 
association of TIO 18 µg and SALM 50 µg BID in reducing 
AECOPDs.23 The primary outcome was the proportion of 
patients in each arm who experienced an AECOPD during 
the 52 weeks of the trial. The trial found no difference in the 
AECOPD proportion between the two arms; however, the 
number of severe exacerbations leading to hospitalization 
was significantly reduced in the FP/SALM plus TIO arm 
compared with the other regimens – incidence rate ratio was 
0.53 (0.33–0.86) compared with TIO alone. However, the 
trial was not powered to study the difference between the 
triple therapy regimen and the FP/SALM arm. Moreover, a 
dropout rate up to 40% in the TIO and TIO plus FP/SALM 
group made the study underpowered to meet the primary 
outcome. 
Interestingly, the definition of COPD exacerbation for 
the TORCH and OPTIMAL trials was similar, described as 
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a deterioration of symptoms that required the use of systemic 
corticosteroids, antibiotics, or hospitalizations.
The INSPIRE was the first study designed to compare an 
ICS-containing regimen and the well-established efficacy of 
TIO in the exacerbation rate in severe patients with COPD.15 
It was a 2-year multicenter, randomized double-blind, double 
dummy controlled trial aimed at comparing the efficacy of 
FP/SALM 500/50 µg BID and TIO 18 µg on the rate of mod-
erate and severe COPD exacerbations over a 2-year period. 
The authors found no difference between the two treatment 
regimens, when both moderate and severe AECOPD were 
grouped and considering AECOPD leading to hospitaliza-
tion. Although the study was not powered to detect such 
differences, patients treated with the ICS-containing regi-
men demonstrated a reduced mortality rate and better QoL 
compared with TIO.15 The INSPIRE was the first study to 
use two parallel definitions of COPD exacerbation: the first 
was event-based, defined as the requirement of health care 
resources, while the second one was symptom-based, accord-
ing to the 1987 Anthonisen criteria.15
Given the aforementioned results and based on the evi-
dence that the association of an ICS/LABA and TIO may 
provide additional clinical benefits than either the treat-
ments alone in the real-life scenario, patients with severe 
airflow obstruction (forced expiratory volume in 1 second 
[FEV
1
] ,50%) were commonly treated with the combina-
tion of TIO and an ICS-containing regimen.24,25 The CLIMB 
(Evaluation of Efficacy and Safety of Symbicort as add-on 
Treatment to Spiriva in Patients with Severe COPD) trial 
was designed to provide clinical efficacy and safety data 
about the triple therapy regimen.24,25 This was a 12-week 
double-blind, parallel group RCT in which, after a run-in 
period on TIO 18 µg, patients with severe COPD (post-
bronchodilator FEV
1
 ,50% predicted) were randomized to 
receive also budesonide (BUD)/FORM 320/9 µg or a match-
ing placebo.24,25 The primary outcome was functional and 
consisted of the change in pre-morning dose of FEV
1
 from 
baseline to week 12. The study met the primary outcome, 
demonstrating the superiority of the triple regimen in improv-
ing lung function in terms of both airflow obstruction and air 
trapping. Among the secondary outcomes, severe exacerba-
tions were analyzed, and the combination of BUD/FORM 
with TIO seemed superior to TIO alone, decreasing the rate 
of severe AECOPD by 62%.24,25 Time to first exacerbation 
and time to first hospitalization were also reduced for the 
study arm treated with the triple regimen. The CLIMB study 
was not powered to effectively detect clinical meaningful 
differences in exacerbation rates, and due to the limited study 
duration, the results obtained, although impacting, were not 
sufficient to confirm their long-term validity. Further and not 
confirming results came from a 6-month RCT that compared 
FP/SALM 500/50 µg BID added to TIO 18 µg and TIO alone 
in COPD patients with moderate to severe airflow obstruc-
tion.26 Also in this case, the primary outcome was based on 
lung function, while the effect on exacerbations was only a 
secondary endpoint. While proving the superiority of the free 
association of FP/SALM and TIO in lung function outcomes, 
the study failed to demonstrate any difference between the 
two treatments in terms of exacerbation rate. Similarly, 
the GLISTEN trial,27 although of limited duration and not 
sufficiently powered for the detection of exacerbation rate 
difference between the study groups, showed that the free 
association of GLY 44 µg and FP/SALM 500/50 µg BID 
was not different in terms of exacerbation rate compared 
with TIO and FP/SALM or FP/SALM alone.
It is important to note that none of the mentioned RCTs 
had, among their inclusion criteria, a consistent history of 
exacerbations. To enter the TORCH study, patients had to 
have at least one exacerbation in the previous 12 months, 
while for the INSPIRE trial, the positive history of AECOPD 
was not numerically specified. The study by Hanania et al,26 
on the contrary, reported that on average only 24% of patients 
had at least one AECOPD in the 12 months before enrol-
ment, making difficult to draw any clinical conclusion on 
exacerbation-related data.
Soon later, Short et al performed the first retrospective 
cohort analysis aimed at comparing the risk of exacerba-
tion and mortality in patients treated with ICS/LABA plus 
TIO or ICS/LABA alone.28 The triple therapy regimen 
resulted to reduce the risk of exacerbation by 29% and the 
hospital admissions by 15% compared with ICS/LABA 
alone during an average follow-up of 4.65 years.28 The 
triple therapy also proved to reduce the all-cause mortal-
ity by 35% compared with ICS/LABA.28 The study was 
limited by its retrospective and observational design, but 
provided further indirect evidence that a combination of 
a LAMA with a ICS/LABA could be beneficial in terms 
of AECOPD prevention.28
The introduction of the first ultra-LABA indacaterol 
(IND) made it possible to test for the first time whether 
a combination of LAMA glycopyrronium with IND was 
able to reduce the risk of exacerbations in patients with 
severe COPD compared with GLY or TIO alone.29 The 
primary aim of the SPARK study29 was to demonstrate 
the superiority of the fixed dose association of IND and 
GLY in reducing the rate of moderate or severe AECOPD 
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compared with GLY. The duration of the study was 64 
weeks (that could be prolonged up to 76 weeks), and the 
study enrolled patients with a severe airflow obstruction and 
with at least one AECOPD in the previous 12 months.29 The 
LABA/LAMA treatment seemed to be superior in reducing 
moderate or severe exacerbations (-12%), mild exacerba-
tions (-15%), and all exacerbations considered together 
(-15%) compared with GLY alone. However, there was 
no statistical difference in the rate of severe exacerbations, 
both compared with TIO and GLY.29
In light of the equivalent effect on AECOPD demon-
strated in the INSPIRE trial and the significant effect of the 
LAMA/LABA combination, although limited mainly on 
mild exacerbation when compared with TIO, the FLAME 
study was designed to offer a direct comparison between 
the LABA/LAMA IND/GLY once daily (OD) and FP/
SALM 500/50 µg BID in a 52-week RCT.17 Accordingly, 
the authors’ primary objective was to demonstrate the 
non-inferiority of the double bronchodilator regimen com-
pared with the ICS/LABA and that the primary outcome 
consisted of the annual rate of all AECOPD (including 
mild, moderate, and severe).17 Included patients had a FEV
1
 
between 25% and 60% predicted and at least one exacerba-
tion in the 12 months prior the enrolment in the study.17 
A significant reduction in the rate of all AECOPDs was 
found in patients treated with IND/GLY group (intention 
to treat [ITT] population RR 0.89 (0.83–0.96), P=0.003); 
this was also true for the time to first exacerbation, for 
which the LABA/LAMA regimen proved to be superior 
to FP/SALM both in moderate or severe and in severe 
AECOPD considered separately.17 However, subgroup 
analyses, especially including patients with very severe 
airflow obstruction, symptomatic patients at low risk of 
exacerbations (GOLD group B), and patients with two 
or more exacerbations in the previous year (the so-called 
frequent exacerbators), showed a possible role of ICS-
containing regimens.17
Studies published before the FLAME trail demonstrated 
a possible correlation between the peripheral eosinophil 
level and the response to ICS in AECOPD reduction. Con-
trary to what is expected, the FLAME trial demonstrated 
a similar effect of the two treatment regimens in patients 
with both ,2% and .2% of serum eosinophils.17 The same 
was reported to be true for cutoff values other than 2% that 
were tested.30 All considered, in the “pre-triple” fixed dose 
combination (FDC) era, the evidence of the efficacy of ICS-
containing regimens in terms of reduction of AECOPD risk 
was mostly derived from data from the secondary outcomes 
and extrapolated from studies comparing an ICS/LABA 
with a LABA alone. Prospective RCT that investigated free 
combination therapies with a LAMA and an ICS/LABA did 
not provide definitive proofs of the superiority of the triple 
therapy compared with ICS/LABA FDC.
Main characteristics and results of the largest RCTs are 
summarized in Table 1.
Focus on FORM, GLY, and BDP
Pharmacokinetics and pharmacodynamics 
of FORM
FORM (eformoterol in the UK) is a β2-adrenoreceptor ago-
nist approved by the European Medicine Agency and the 
Food and Drug Administration for the maintenance treatment 
of COPD and asthma. It is a phenylethanolamine deriva-
tive, a pure diastereomer of the R,R- and S,S-enantiomers 
of 2-hydroxy-5-[(1R,S)-l-hydroxy-2-][(1R,S)-2-(p-
methoxyphenyl)-l-methylethylamino] formanilide prepared 
as the fumarate dihydrate salt. Its structural features allow 
a high selectivity, intrinsic activity, and very high affinity 
at the β2-adrenoceptor.31 Relatively high water solubility 
and moderate lipophilicity ensure rapid access of inhaled 
FORM to the β2-adrenoceptor on bronchial smooth muscle 
cells and rapid bronchodilation.31 In contrast to the LABA 
SALM, the uptake of FORM by airway smooth muscle cells 
is dependent on organic cation transporter 3.32 The lipophilic-
ity of FORM also explains its prolonged duration of action,33 
and the possibility to be stored in cell membranes, making a 
depot from which the drug is available to β2-adrenoceptors 
on bronchial smooth muscle cells.34 The reported pKi (nega-
tive logarithm of the equilibrium dissociation constant of a 
ligand determined in inhibition studies) for FORM are from 
6.07±0.04 to 6.12±0.09 and from 7.84±0.05 to 8.29±0.03, for 
β1 and β2 receptors, respectively, while the intrinsic activity 
(% isoprenaline) varies between 90 to 100, depending on 
the reports.35 FORM also has the highest bronchoselectivity 
compared with β2-adrenoceptor agonists isoproterenol, 
orciprenaline, trimetoquinol, and albuterol.36 The functional 
selectivity (ratio β1:β2) of FORM ranges from 1:13 to 1:166 
and SALM from 1:525 to 1:3,000.35
The bronchodilator effect of FORM in animal models was 
the most potent compared with other four β2-adrenoceptor 
agonists (isoproterenol, orciprenaline, trimetoquinol, 
and albuterol), after either subcutaneous, oral, or aerosol 
administration.36,37 FORM’s high affinity for β2-adrenocep-
tors and high intrinsic efficacy are also responsible for dose-
related inhibition of histamine-induced bronchoconstriction, 
being 10- to 20-fold more potent than either albuterol or 
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SALM.36,38,39 In vitro and in vivo studies have shown that 
FORM has a fast onset of action that occurs within minutes 
after inhalation,38,40 comparable to that of albuterol and faster 
than SALM.39 Fast onset of action was described for FORM 
12 µg (Modulite®) administered alone or in combination with 
TIO 18 µg during mild and moderate COPD acute exacerba-
tions.41 The duration of action of FORM, approved as a BID 
administration of LABA, is longer than that of albuterol but 
markedly shorter than that of SALM.42
Pharmacokinetics and pharmacodynamics 
of GLY
GLY, the active moiety of its bromide salt glycopyrro-
late, is an antimuscarinic drug, first approved by the Food 
and Drug Administration (FDA) for the management of 
sialorrhea due to preoperative stages, neuromusclular 
and drug-related diseases, and gastric secretions.43,44 It 
is a quaternary ammonium derivative initially approved 
by FDA, European Medicines Agency, and in Japan as a 
monotherapy for COPD.45 In Europe, GLY was approved 
with a OD posology, whereas in the USA the BID regimen 
is recommended. Recently, FDA approved its BID posology 
in combination with fluticasone at a dosage of 9 µg BID 
delivered with a pressurized metered-dose inhaler (pMDI) 
formulation. GLY is rapidly absorbed into the systemic 
circulation after inhalation, ≈90% via lung and ≈10% via 
gastrointestinal absorption.46
The mean terminal elimination half-life (t
1/2
) of GLY in 
dry powder inhaler formulations is half that reported for GLY 
delivered by pMDI (from 13 to 22 hours for a dose range of 
25 to 200 µg and from 6.3 to 9.6 hours for a dose range of 
14.4 to 115.2 µg, respectively).47
GLY is a competitive muscarinic receptor antagonist that 
bronchodilates the airways by inhibiting acetylcholine-induced 
bronchoconstriction in bronchial smooth muscle cells.48
The three main muscarinic receptors related to human 
lung bronchial dynamics are the M1, M2, and M3 receptors. 
M2 receptor protects against bronchoconstriction and its 
block may increase heart rate.48,49 M1 and, especially, M3 
receptors are thought to be the prime mediators of the vagal-
induced bronchoconstriction.46,48 In vitro, GLY has 4- to 
5-fold higher selectivity for human M1 and M3 receptors 
compared with M2 receptor.46,50 GLY has a faster onset of 
action in both in vitro and in vivo animal models compared 
with TIO.50 The lower equilibrium binding affinity constants 
and the faster kinetic off rate justify the faster onset of action 
in patients with moderate to severe COPD compared with 
tiotropium bromide.51 In patients with severe COPD, GLY 
showed a fast and comparable ability to improve static lung 
volumes compared with aclidinium.52
GLY has been shown to be more potent than ipratropium 
bromide and tiotropium bromide in terms of concentration 
drug necessary to inhibit the contractile response by 50%.53
Pharmacokinetics and pharmacodynamics 
of BDP
BDP is the dipropionate ester of the free form beclometha-
sone-17-monopropionate, a synthetic halogenated gluco-
corticoid. BDP is a prodrug that must be activated through 
enzymatic processes in the lungs.45 Despite its higher oral 
availability compared with other ICSs, its prodrug form 
reduces the risk of local pharyngeal side effects, while it 
may favor a better pulmonary targeting, with 95% of bec-
lomathasone that reaches the lung being transformed in its 
active form BDP delivered by pMDI has showed one of 
the highest lung deposition rates, reaching .50% of the 
delivered dose.54,55
BDP has the lower known receptor affinity among mostly 
used ICSs. Given the binding ability of dexamethasone as 
100, BDP has 53, while for comparison, salmeterol has a 
receptor affinity of 1,800. Although a higher affinity may 
signify higher potency, and thus, the possibility to employ 
lower dosages to exert the desired effect, a higher binding 
ability, may promote adverse effects.56,57 Nonetheless, given 
different binding affinities, ICSs may exert similar pulmonary 
targeting and thus similar anti-inflammatory effects. 
Interaction and advantages of triple 
combination therapy
The small airways are the major and earlier site of lung 
damage in COPD,58 and their dysfunction is responsible for 
pathophysiological effects that withstand respiratory symp-
toms such as dyspnea, airway hyper-responsiveness, and 
exercise limitation. Both LABAs and LAMAs have demon-
strated beneficial effects in terms of reduction in air trapping, 
closing volume, and airway stretching,59–61 especially when 
administered together.62 The rationale of combining a LABA 
and a LAMA relies on the synergistic effect exerted by the 
two classes of bronchodilators at the pre-junctional and 
intracellular levels.62 In fact, the stimulation of pre-junctional 
β2-receptors both reduce the intracellular calcium concentra-
tion, thus reducing the release of acetylcholine, and stimulate 
adenylyl cyclase that indirectly allows the release of acetyl-
coline in the synaptic space. On the contrary, LAMAs inhibit 
M3 receptors and amplify the bronchodilation induced 
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by LABAs. Moreover, more complex additive effects are 
elicited through the intracellular crosstalk between M3, M2, 
and β2-receptors. However, low and iso-effective concentra-
tions are needed in order to express a significant additive 
bronchodilation effect on the airways, the latter being more a 
class effect rather than being linked to a specific molecule.63 
A dose–response trial that evaluated the most effective 
concentration of extra fine GLY added to extra fine BDP/
FORM 200/12 µg FDC daily demonstrated that the dose of 
25 µg exerts the ideal dose–effect in bronchodilation when 
compared with BDP/FORM alone and GLY doses of 12.5 
and 50 µg.64 In addition, the combination of FORM and 
BDP proved to have a strong synergistic effect at very low 
doses (6 and 100 µg, respectively) in small hyper-responsive 
human airways. Despite the great technological evolution 
during recent years, inhaled drug deposition is jeopardized 
by lung ventilation inhomogeneity, unpredictable regional 
airflow/obstruction characteristics, and the impacts of major-
ity of inhaled drugs in the larger airways. The possibility of 
a synergistic effect at very low doses becomes crucial when 
considering the bronchodilator and anti-inflammatory effects 
exerted at the small airway level. In fact, the increased small 
particle fraction granted by the pMDI formulation of BDP/
FORM/GLY should promote a better peripheral drug depo-
sition, thus allowing for clinical effectiveness despite the 
small absolute amount of active drug.65 Although currently 
no in vitro study has evaluated the iso-effectiveness and the 
proportionality of the GLY and FORM dosages in the triple 
FDC, the effects of the triple therapy observed in patients 
with recurrent exacerbations and a consistent small airway 
damage represent a first evidence of the balance and func-
tion and clinical effectiveness of this combination. While 
the synergistic effect of the combination of aclidinium and 
FORM or GLY and IND has been proven in in vitro and 
translational studies, this is not true for the combination of 
vilanterol (VI, under-dosed) and umeclidinium (UMEC, 
over-dosed).63,66
Triple therapy for the management 
of moderate/severe exacerbations 
The TRILOGY, FULFIL, and TRINITY studies were the 
three RCTs that evaluated the efficacy of FDC triple therapy 
in COPD for the first time.18–20
TRIBUTE22 and IMPACT21 were recently published 
and add new important information about this therapeutic 
approach to COPD treatment. The TRILOGY,18 TRINITY,20 
and TRIBUTE22 trials compared the efficacy of the FDC 
of BDP/FORM/GLY 100/6/12.5 µg with the FDC of 
BDP/FORM (TRILOGY), the free combination of BDP/
FORM with TIO or TIO alone (TRINITY), and the FDC 
of the LABA/LAMA IND/GLY (TRIBUTE). The FUL-
FIL trial19 compared the efficacy of the FDC of fluticasone 
furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 
µg with the FDC of BUD/FORM, while the IMPACT study21 
compared the FF/UMEC/VI FDC with the LAMA/LABA 
FDC UMEC/VI and the ICS/LABA FDC FF/VI.
Trilogy was a randomized, parallel group, double-blind, 
active-controlled study performed in 159 sites across 14 countries 
that compared the efficacy of the combination of ICS/LABA/
LAMA, namely BDP/FORM/GLY in one inhaler with the 
fixed combination of BDP/FORM over 52 weeks.18
FULFIL trial was a Phase III, randomized, double-blind, 
double-dummy, parallel group, multicenter study that compared 
the efficacy of the combination in one inhaler of FF, UMEC, 
VI to BUD/FORM over 24 weeks.19 The study was designed 
to evaluate the efficacy in term of change of FEV
1
 from base-
line at 24 weeks in all randomized subjects. An extension 
of the study up to 52 weeks was intended in a subgroup of 
patients for safety purposes.19
TRINITY was a randomized, parallel group, double-
blind, double-dummy, active-controlled 1-year trial, per-
formed in 224 sites across 15 countries that compared the 
efficacy of three different treatments: BDP/FORM/GLY 
FDC; TIO monotherapy; and the combination therapy with 
BDP/FORM added to TIO.20
IMPACT was a randomized, double-blind, parallel-group, 
multicenter trial on Phase III that compared the efficacy over 
52 weeks of OD combination of FF (100 µg), UMEC at the 
dose of 62.5 µg and VI (25 µg) on the combination of FF/VI 
or the combination of UMEC/VI.21
TRIBUTE was a randomized, parallel group, double-
blind, double-dummy, active-controlled Phase IIIb study 
that compared the effect of one inhaler combination of two 
bronchodilator, namely IND 85 µg/GLY 43 µg OD and one 
inhaler triple therapy with BDP/FORM/GLY nominal dose 
respectively of 100 µg/6 µg/9 µg BID.22
The studies explored different aspects of the disease; 
TRILOGY and FULFILL set lung function and QoL as the 
primary outcomes and evaluated AECOPDs as secondary 
outcomes while TRINITY, IMPACT, and TRIBUTE evalu-
ated moderate and severe AECOPDs as the main outcomes 
(Table 1).
TRILOGY study randomized 1,368 patients while 1,810 
patients were included in the ITT population of the FULFIL 
study and 430 were included in the extension (EXT) popula-
tion. Both the studies demonstrated that adding a LAMA to 
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different combinations of ICS/LABA improved lung function 
and QoL, but not dyspnea.18,19
In the TRILOGY study, the percentage of patients who 
had moderate-to-severe AECOPD was lower with BDP/
FORM/GLY (31%) than with BDP/FORM (35%). The 
adjusted annual rate of moderate-to-severe exacerbations 
was 0.41 for the BDP/FORM/GLY group and 0.53 for 
the BDP/FORM group, with a rate ratio of 0.77 (95% CI 
0.65–0.92; P=0.005), indicating a significant 23% reduction 
in the exacerbation rate with BDP/FORM/GLY. Subgroup 
analyses of patients with more than one AECOPD have 
shown a more consistent treatment effect, with a reduction 
rate of moderate/severe AECOPD of 33% in patients treated 
with BDP/FORM/GLY compared with the BDP/FORM 
group (rate ratio 0.67 [95% CI 0.48–0.94]; P=0.019), 
whereas a minor effect could be found in the subgroup 
of patients with a history of one exacerbation or less in 
the previous 12 months (RR 0.83 [95% CI 0.67–1.02]; 
P=0.074).18
Different from TRINITY and TRILOGY trials, the 
FULFIL inclusion criteria were based not solely on exacerba-
tions history, but included patients who belonged to group D 
according to GOLD classification 2016, that is, either patients 
with a FEV
1
 ,50% predicted and increased symptoms or 
patients with $1 severe exacerbation or $2 mild/moderate 
AECOPD. In the ITT population, 65% of patients had at 
least one moderate/severe exacerbation. The incidence rates 
of moderate/severe AECOPD over the 24-week treatment 
period were 10% and 14% for FF/UMEC/VI and BUD/
FORM, respectively. The mean annualized rates of moderate/
severe exacerbations in the ITT population were 0.22 and 
0.34 for FF/UMEC/VI and BUD/FORM, respectively, 
while the reduction in the annualized rate was statistically 
significant for FF/UMEC/VI (35%; 95% CI 14%–51%; 
P=0.002).19 Patients treated with FF/UMEC/VI experienced 
AECOPDs less frequently leading to hospitalization (n=12, 
1%) compared with the BUD/FORM treatment group 
(n=22, 2%).19
AECOPDs were the focus in the TRINITY, IMPACT, 
and TRIBUTE studies that were designed to evaluate the 
rate of moderate/severe AECOPDs as the primary endpoint. 
In the TRINITY study, the comparison was made between 
the triple therapy and the LAMA alone and not compared 
with ICS/LABA.20
The results show that in the FDC triple therapy (BDP/
FORM/GLY) group, the exacerbation rates were 0.46 (0.41–
0.51) per patient, while in the TIO arm were 0.57 (0.52–0.63) 
with an RR of 0.80 (95% CI 0.69–0.92; P=0.0025). In the 
BDP/FORM plus TIO in open, the exacerbation rate was 
0.45 (0.39–0.52) with a lower RR compared with patients 
treated with TIO (RR 0.79; 95% CI 0.66–0.94; P=0.0095).20 
No difference was found with the FDC triple therapy (RR 
1.01; 95% CI 0.85–1.21; P=0.89).20
The TRINITY study explored the effect of the inhaled 
treatment on exacerbation also in terms of the time to first 
moderate-to-severe exacerbation as a secondary endpoint.20 
The results have shown that FDC triple therapy was able to 
prolong the time to the next exacerbation compared with TIO 
alone with a hazard ratio (HR) of 0.84 (95% CI 0.72–0.97; 
P=0.0154).20 However, the effect was similar compared with 
the group treated with BDP/FORM plus TIO in open (HR 
1.06; 95% CI 0.88–1.27; P=0.57).20
TRIBUTE was a randomized, parallel group, double-blind, 
double-dummy, active-controlled Phase IIIb trial that com-
pared the efficacy of the FDC of BDP/FORM/GLY 
100/6/12.5 µg two actuations BID with the LABA/LAMA 
FDC IND/GLY 85/43 µg OD.22 In the TRIBUTE trial, 87% 
of the 764 patients assigned to the BDP/FORM/GLY treat-
ment group and 84% of the 768 patients assigned to IND/
GLY completed the study, with an adjusted rate ratio of 
moderate/severe AECOPD of 0.50 per patient/per year (95% 
CI 0.45–0.57) and 0.59 (95% CI 0.53–0.67), respectively.22 
After 52 weeks of treatment, the FDC triple therapy showed 
a 15% reduction in moderate and severe exacerbation rate 
compared with the LABA/LAMA FDC, with an adjusted 
rate ratio of 0.85 (95% CI 0.72–0.99; P=0.043).22 No signifi-
cant differences in the exacerbation rate were found between 
the two treatment groups when moderate and severe exacer-
bations were analyzed separately. The annual exacerbation 
rate was significantly reduced by the FDC triple therapy in 
patient with $2% of peripheral eosinophils (RR 0.806; 95% 
CI 0.664–0.978; P=0.029), and the trend was maintained 
considering the absolute cutoff of 200 eosinophils/µL (RR 
0.806; 95% CI 0.646–1.007; P=0.057).22 An increase rate 
of pneumonia was not present in patients treated with BDP/
FORM/GLY, while atrial fibrillation was more frequently 
observed in the IND/GLY group.22
The IMPACT was a Phase III, randomized, double-blind, 
parallel-group, multicenter trial. The primary outcome was 
the effect of the FDC of FF/UMEC/VI 100/62.5/25 µg OD 
compared with the LABA/LAMA combination of UMEC/
VI 100/25 µg OD and the ICS/LABA FDC of FF/VI 
100/25 µg OD in terms of moderate or severe AECOPD 
rate after 52 weeks of treatment. Patients were enrolled if 
they had a COPD assessment test (CAT) score $10 and 
either a FEV
1
 ,50% predicted and a history of at least 
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one moderate or severe exacerbation in the previous year, 
or a FEV
1
 between 50% and 80% predicted and at least two 
moderate exacerbations or one severe exacerbation in the 
previous year.21 At the end of the study period, the rate of 
moderate or severe exacerbations in triple therapy group was 
0.91 per year compared with an annual rate of 1.07 for the 
FF/VI group (RR 0.85; 95% CI 0.80–0.90; P,0.001) and 
1.21 in the UMEC/VI group (RR 0.75; 95% CI 0.70–0.81), 
suggesting a significant reduction in the rate of moderate and 
severe AECOPDs of 15% and 25%, respectively.21 Consider-
ing severe AECOPDs only, the latter were low and the annual 
rate did not significantly differ (0.13 vs 0.15) between the 
triple therapy groups compared with the group treated with 
ICS/LABA (RR 0.87; 95% CI 0.76–1.01; P=0.06). However, 
a statistically significant 35% reduction (P,0.001) in severe 
exacerbations was reached comparing the effect of triple 
FDC with the LAMA/LABA UMEC/VI (RR 0.66; 95% CI 
0.56–0.78). Concurrently, patients with .150 eosinophil/µL 
showed a not significant trend in reduction of moderate/
severe exacerbations when treated with triple therapy in 
FDC21 (Figure 1).
The annual rate of pneumonia was significantly increased 
in patient treated with FF-containing regimens. The time to 
the first pneumonia event in patients treated with the FDC 
triple therapy and in the UMEC/VI group differed signifi-
cantly (RR 1.53; 95% CI 1.22–1.92; P,0.001), while no 
difference was found between the ICS-containing regimens.21 
One of the main limitation of the study was the inclusion 
of a significant number of patients with an asthmatic trait, 
since 18% of the study sample had a significant reversibility 
defined as an increase of 12% and 200 mL from baseline after 
an acute bronchodilation test.67
Perspective
Making a research on ClinicalTrials.gov using the keywords 
“Chronic Obstructive Pulmonary Disease” and “Exacerbation” 
with the filter “Recruiting” and “not yet Recruiting” studies, 
by May 2018, we found 123 studies; of these, 11 evaluate 
the impact of inhaled treatments on AECOPDs and four are 
focused on triple therapy.
The SOPHOS study (NCT02727660)68 is a Phase III 
randomized, double-blind, parallel group, multicenter, 1-year 
Figure 1 Relative rate ratio for moderate/severe and severe COPD exacerbations in trials investigating efficacy of fixed-dose triple therapy compared with LABA/ICS, LAMA, 
LABA/LAMA, or open triple therapy. 
Notes: vertical bars represent the upper limit of the CI. The red line represents a CI =1.0 and therefore the significance level. #Rate of severe exacerbations not reported; 
*Relative risk for severe exacerbations not available.
Abbreviations: MOD/Sev, moderate/severe exacerbations; Sev, severe exacerbations; LABA, long-acting β2-agonists; ICS, inhaled corticosteroids; LAMA, long-acting 
muscarinic antagonist; AECOPD, acute exacerbations of COPD; FF, fluticasone furoate; BDP, beclomethasone dipropionate; FORM, formoterol; BUD, budesonide; GLY, 
glycopyrronium; TIO, tiotropium; IND, indacaterol; UMeC, umeclidinium; vI, vilanterol.
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trial completed in April 2018. It evaluates the effect of 
different doses of BUD/FORM delivered via pMDI compared 
with FORM alone on the reduction of mild, moderate, and 
severe exacerbations in COPD patients with severe airflow 
obstruction. At the moment, no study results are have been 
made available.68
TRIVERSYTI (NCT03197818) is an ongoing 24-week, 
double-blind, double-dummy, randomized, multinational, 
multicenter, two-arm parallel group, actively controlled 
clinical trial that compares the efficacy of the FDC BDP/
FORM/GLY delivered via pMDI with the FDC BUD/FORM 
in terms of lung function and time to first exacerbation in 
patients with severe COPD.69
Finally, ETHOS (NCT02465567)70 and AIRWISE 
(NCT03265145)71 compare the effect of adding an ICS to a 
LABA/LAMA FDC treatment in the reduction of moderate/
severe AECOPD in severe COPD patients. The ETHOS study 
tests different doses of the FDC of BUD/FORM/GLY with 
FF/GLY delivered via pMDI,70 while the AIRWISE study 
compares the TIO/olodaterol FDC with an ICS/LABA + 
LAMA regimen.71 The first study is planned to be competed 
by December 2018 and the second by January 2020. 
Pharmacological prevention of 
moderate and severe COPD 
exacerbations
The triple therapy approach is one of the proposed options 
for the management of patients with frequent exacerbations. 
Although the initial strategy should be based upon treatment 
with a LABA/LAMA combination that had proved efficient 
in the reduction of mild and moderate AECOPDs, a definitive 
evidence on severe AECOPDs is still lacking. The evidence 
from trials investigating triple therapy regimens explored the 
effect of adding a second bronchodilator to an ICS/LABA 
regimen and the effect of adding an ICS to a LABA/LAMA 
treatment. Taken together, the results of the RCTs published 
so far show that there are good evidence that triple FDC 
combination is superior to TIO alone in the prevention of 
moderate to severe AECOPD. The evidence on the preven-
tion of AECOPDs from the TRILOGY18 and FULFIL19 
trials seem to suggest that FDC triple therapy could reduce 
moderate and severe exacerbations more effectively than 
an ICS/LABA combination therapy. The effect seems to be 
more pronounced in patients with more than one moderate/
severe AECOPD in the year preceding the enrolment. The 
IMPACT and TRIBUTE trials were specifically designed 
to explore the effect of a triple FDC therapy in the reduc-
tion of moderate and severe exacerbations in patients with a 
severe airflow obstruction and with a significant history of 
exacerbations.21,22 Data from these two large trials indicate 
a positive effect of the triple combination therapy in terms 
of reduction in moderate/severe exacerbations taken as 
a whole. However, when comparing the triple FDC with 
LABA/LAMA in the reduction of severe exacerbations, 
data are discordant. In fact, while patients treated with the 
FF/UMEC/VI FDC were less exposed to severe AECOPDs 
when compared with patients treated with the UMEC/VI regi-
men, the same was not apparent when comparing the effects 
of BDP/FORM/GLY and IND/GLY FDCs. The percentage 
of frequent exacerbators (patients with $2 exacerbations in 
the previous year) in the IMPACT trial was around 47% in 
each treatment arm,21 while the latter was low as 20% and 
18% in the BDP/FORM/GLY and IND/GLY arms in the 
TRIBUTE trial. This large difference in the characteristics 
of the study populations between the two trials may have 
hindered the possible differences between the ICS/LABA/
LAMA and LABA/LAMA in terms of reduction in severe 
exacerbations in the TRIBUTE study.22
Confirming previous observations,17,30 the effect of the 
triple therapy in the IMPACT trial seemed to be independent 
of the peripheral eosinophil level. On the contrary, results 
from the TRIBUTE trial suggest that patients with $2% 
of serum eosinophils could respond better to an FDC triple 
therapy in the prevention of exacerbations. Recent evidence 
from the SUNSET trial72 shows that stepping down from 
triple therapy to a LAMA/LABA combination in non-frequent 
exacerbators can be safe in patients with an eosinophil 
count #300 cells/µL, while patients with higher eosinophil 
concentration may experience a larger decrease in lung func-
tion and a slightly higher risk of future exacerbation. Based on 
these results, eosinophils may still have a role in the decision-
making for long-term COPD treatment, but, as also previously 
stated by Calverley,73 the most important and consistent 
parameter seems to be the history of moderate and severe 
exacerbations in patients already treated with a LABA/LAMA 
therapy. No less importantly, data from the IMPACT study 
confirm the possible increased risk of pneumonia in patients 
treated with fluticasone-containing inhaled regimens.
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